CAS: 79822-46-1; 4-(Tert-Butyl)-3-Methoxybenzoic Acid

上下游产品

CAS号88-40-4 2-tert-butyl-5-... | CAS号7697-37-2 硝酸 | CAS号35291-92-0 4-tert-butyl-3-...

2-叔丁基-5-甲基苯甲醚置于potassium Permanganate体系中,化学反应生成 3-甲氧基-4-叔丁基苯甲酸
参考文献:N-酰基吡咯烷的不对称合成抑制hcv聚合酶
标题:N-酰基吡咯烷的不对称合成抑制hcv聚合酶
摘要:描述了多公斤级的高度取代的n-酰基吡咯烷的实际不对称合成.构建三个立体中心的关键步骤是丙烯酸甲酯和由1-亮氨酸t制备的亚氨基酯的[3 + 2]环加成反应.丁酯盐酸盐和2-噻唑甲醛.通过乙酸银和金鸡纳生物碱(特别是对苯二酚)的络合物,具有完全的非对映异构体控制和高达87%的对映体控制,可实现新型的不对称催化.生物碱既用作配体,又用作形成甲亚胺叶立德或1,3-偶极的基础.实验表明,对苯二酚的羟基是观测到的对映选择性的关键元素.环加成方法也适用于甲基乙烯基酮,根据所使用的反应条件,可以接触到4-乙酰基吡咯烷的α-或β-受体.该合成还强调了有效的n酰化,选择性o-对n-甲基化,以及由nab(oac)3 H催化的nabh 4-Meoh独特的酯还原反应,不仅可以实现出色的化学选择性,而且还可以避免形成不需要的但热力学上受人欢迎的差向异构体.从1-亮氨酸叔丁酯盐酸盐以七个线性步骤合成高度官能化的靶标,所有三个分离的中间体均为高度结晶.
DOI:10.1021/jo800062C

专利信息

专利号:US-7807709-B2
优先权日:2005-03-23
标题 :Organic compounds
发明人：EHRHARDT CLAUS; IRIE OSAMU; LORTHIOIS EDWIGE LILIANE; MAIBAUM JUERGEN KLAUS; OSTERMANN NILS; SELLNER HOLGER
权利人:NOVARTIS AG
摘要:The invention relates to the use of (3,4-di-, 3,3,4-tri, 3,4,4-tri- or 3,3,4,4-tetra-)substituted pyrrolidine compounds for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; compounds that are part of a subclass of these substituted pyrrolidine compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; new compounds that are part of a subclass of these substituted pyrrolidine compounds; pharmaceutical formulations comprising said substituted pyrrolidine compounds, and/or a method of treatment comprising administering said substituted pyrrolidine compounds, a method for the manufacture especially of said new substituted pyrrolidine compounds, as well as novel intermediates, starting materials and/or partial steps for their synthesis.